Effectiveness and safety of Shenqi Fuzheng injection combined with platinum-based chemotherapy for treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis

Frontiers in Oncology

Oncology

Chenxi Qiao¹  Shuaihang Hu¹  Zheng Li¹  Wei Hou¹  Dandan Wang¹  Xiumei Ma¹  Xinyan Wang²  Zhuo Wang²  Kangdi Cao² 

[1] Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China;Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China;Graduate School of Beijing University of Chinese Medicine, Beijing, China;

关键词: non-small cell lung cancer;    platinum-based chemotherapy;    Shenqi Fuzheng injection;    efficacy and safety;    randomized controlled trial;    systematic review;    meta-analysis 2.2 retrieval strategy;   

DOI  :  10.3389/fonc.2023.1198768

 received in 2023-04-02, accepted in 2023-08-08,  发布年份 2023

来源: Frontiers

【 摘 要 】

ObjectiveTo evaluate the efficacy and safety of Shenqi Fuzheng Injection (SFI) combined with platinum-based chemotherapy (PBC) for the treatment of advanced non-small cell lung cancer (NSCLC).MethodsSeven electronic databases, including CNKI and Wanfang, were comprehensively searched to screen randomized controlled trials (RCTs) until May 1, 2022. The quality of each trial was evaluated according to the Cochrane Handbook for Systematic Reviews of Interventions, and systematic reviews were conducted according to the PRISMA guidelines. Statistical analysis was performed using Review Manager 5.3, and the results were expressed as relative risk (RR) and 95% confidence interval (95% CI). The primary outcome measures were objective response rate (ORR) and disease control rate (DCR). The secondary outcome measures were quality of life and toxicity. Subgroup analysis was performed according to the number of days of SFI single-cycle treatment and combined PBC regimen.ResultsA total of 44 RCTs involving 3475 patients were included in the study. The meta-analysis results showed that, compared with PBC alone, SFI combined with PBC significantly improved the ORR (RR = 1.27, 95% CI = 1.18–1.37, P < 0.00001), DCR (RR = 1.12, 95% CI = 1.08–1.15, P < 0.00001), and quality of life (RR = 1.41, 95% CI = 1.31–1.52, P < 0.00001). It also reduced chemotherapy-induced hemoglobin reduction (RR = 0.57, 95% CI = 0.48–0.67, P < 0.00001), leukopenia (RR = 0.61, 95% CI = 0.53–0.71, P < 0.00001), thrombocytopenia (RR = 0.62, 95% CI = 0.55–0.70, P < 0.00001), and simple bone marrow suppression (RR = 0.55, 95% CI = 0.41–0.73, P < 0.0001). Nausea and vomiting (RR = 0.63, 95% CI = 0.52–0.77, P < 0.00001), diarrhea (RR = 0.48, 95% CI = 0.37–0.64, P < 0.00001), and simple digestive tract reactions (RR = 0.63, 95% CI = 0.49–0.80, P = 0.0002) also decreased with the treatment of SFI.ConclusionSFI combined with PBC for the treatment of advanced NSCLC improved the ORR, DCR, and quality of life, and reduced the incidence of myelosuppression and gastrointestinal adverse reactions. However, considering the limitations of existing evidence, further verification using high-quality RCTs is required.Systematic review registrationhttps://inplasy.com/inplasy-2022-7-0026, identifier INPLASY202270026.

【 授权许可】

Unknown   
Copyright © 2023 Qiao, Hu, Wang, Cao, Wang, Wang, Ma, Li and Hou